Dublin-based Alkermes plc announced positive results from an early-stage stage study, evaluating its novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). The company announced positive topline results from a Phase I study of ALKS 8700, the company’s reformulated version of Biogen Idec’s blockbuster MS …